Xbrane Biopharma Q2 FY26 net loss widens to SEK 11.4 million; revenue rises to SEK 46.8 million

• Xbrane Biopharma posted Q2 revenue of SEK 46.8 million, up 17.29% year on year.
• Q2 net loss widened to SEK 11.4 million, swinging from a profit a year earlier; EPS turned to a loss of SEK 0.55.
• Q2 EBITDA loss widened to SEK 6.3 million, while cash climbed to SEK 49.5 million at period-end.
• First-half revenue fell 51.84% to SEK 64.1 million, while the net loss narrowed to SEK 24.5 million.
• Resubmitted a Lucentis biosimilar BLA; FDA set an Oct. 29, 2026 BsUFA date, revised Intas deal, signed JOINN partnership for Xdarzane.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xbrane Biopharma AB published the original content used to generate this news brief on July 17, 2026, and is solely responsible for the information contained therein.